Table 1.

Characteristics of patients with colitis versus self-limited diarrhea

Ipilimumab-induced colitisGastrointestinal symptoms
Mean (SD)Mean (SD)
SubgroupTotal
N465399
Gender, n (%)P
 Male31 (67.4%)34 (63%)
 Female15 (32.6%)20 (37%)
0.64
Age65.3 (±13.8)58.13 (±13.4)0.01
BMI28.4 (±4.9)29.1 (±5.9)0.51
LDH236.8 (±203)290 (±255)0.25
Number of doses before onset of symptoms3 (±1.3)2.5 (±1.2)0.052
Days to onset of symptoms53.6 (±35)72.8 (±79)0.13
Days to resolution of symptoms38.3 (±29)6.3 (±7.9)1.23 × 108
Days per dose of ipilimumab (dose density)17.9 (± 9.0)24.7 (±21.2)0.04
  • NOTE: Of the 99 patients who developed gastrointestinal symptoms after receiving ipilimumab, 46 patients were diagnosed with immune-related colitis. The demographic and clinical characteristics between the two patient groups (colitis vs. diarrhea not attributed to colitis) are outlined. Bold: significant P values (< 0.05)